


PHARMACEUTICAL 2023

Zentalis Pharmaceuticals Inc. Rank 145 of 446









PHARMACEUTICAL 2023



Zentalis Pharmaceuticals Inc. Rank 145 of 446

The relative strengths and weaknesses of Zentalis Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zentalis Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Zentalis Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 158%, being 115% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	451,933
Cost of Goods Sold	0
Intangible Assets	3,736
Liabilities, Current	56,647
Liabilities, Non-Current	47,786
Other Assets	75,936
Other Compr. Net Income	-921
Other Expenses	-469
Other Liabilities	853
Other Net Income	-10,295
Other Revenues	0
Property and Equipment	7,705
Research and Development	172,734
Selling, General and Administrative Expense	54,553

Output Variable	Value in 1000 USD
Assets	539,310
Liabilities	105,286
Expenses	226,818
Revenues	0
Stockholders Equity	434,024
Net Income	-237,113
Comprehensive Net Income	-237,574
Economic Capital Ratio	158%

